{
    "title": "To permit commercial importation of prescription drugs from Canada, and for other purposes.",
    "content": "SECTION 1. IMPORTATION OF PRESCRIPTION DRUGS.\n\n    (a) In General.--Chapter VIII of the Federal Food, Drug, and \nCosmetic Act (21 U.S.C. 381 et seq.) is amended by striking section 804 \nand inserting the following:\n\n``SEC. 804. IMPORTATION OF PRESCRIPTION DRUGS.\n\n    ``(a) Definitions.--In this section:\n            ``(1) Importer.--The term `importer' means a pharmacist or \n        wholesaler.\n            ``(2) Pharmacist.--The term `pharmacist' means a person \n        licensed by a State to practice pharmacy, including the \n        dispensing and selling of prescription drugs.\n            ``(3) Prescription drug.--The term `prescription drug' \n        means a drug subject to section 503(b), other than--\n                    ``(A) a controlled substance (as defined in section \n                102 of the Controlled Substances Act (21 U.S.C. 802));\n                    ``(B) a biological product (as defined in section \n                351 of the Public Health Service Act (42 U.S.C. 262));\n                    ``(C) an infused drug (including a peritoneal \n                dialysis solution);\n                    ``(D) an intravenously injected drug; or\n                    ``(E) a drug that is inhaled during surgery.\n            ``(4) Qualifying laboratory.--The term `qualifying \n        laboratory' means a laboratory in the United States that has \n        been approved by the Secretary for the purposes of this \n        section.\n            ``(5) Wholesaler.--\n                    ``(A) In general.--The term `wholesaler' means a \n                person licensed as a wholesaler or distributor of \n                prescription drugs in the United States under section \n                503(e)(2)(A).\n                    ``(B) Exclusion.--The term `wholesaler' does not \n                include a person authorized to import drugs under \n                section 801(d)(1).\n    ``(b) Regulations.--The Secretary, after consultation with the \nUnited States Trade Representative and the Commissioner of Customs, \nshall promulgate regulations permitting pharmacists and wholesalers to \nimport prescription drugs from Canada into the United States.\n    ``(c) Limitation.--The regulations under subsection (b) shall--\n            ``(1) require that safeguards be in place to ensure that \n        each prescription drug imported under the regulations complies \n        with section 505 (including with respect to being safe and \n        effective for the intended use of the prescription drug), with \n        sections 501 and 502, and with other applicable requirements of \n        this Act;\n            ``(2) require that an importer of a prescription drug under \n        the regulations comply with subsections (d)(1) and (e); and\n            ``(3) contain any additional provisions determined by the \n        Secretary to be appropriate as a safeguard to protect the \n        public health or as a means to facilitate the importation of \n        prescription drugs.\n    ``(d) Information and Records.--\n            ``(1) In general.--The regulations under subsection (b) \n        shall require an importer of a prescription drug under \n        subsection (b) to submit to the Secretary the following \n        information and documentation:\n                    ``(A) The name and quantity of the active \n                ingredient of the prescription drug.\n                    ``(B) A description of the dosage form of the \n                prescription drug.\n                    ``(C) The date on which the prescription drug is \n                shipped.\n                    ``(D) The quantity of the prescription drug that is \n                shipped.\n                    ``(E) The point of origin and destination of the \n                prescription drug.\n                    ``(F) The price paid by the importer for the \n                prescription drug.\n                    ``(G) Documentation from the foreign seller \n                specifying--\n                            ``(i) the original source of the \n                        prescription drug; and\n                            ``(ii) the quantity of each lot of the \n                        prescription drug originally received by the \n                        seller from that source.\n                    ``(H) The lot or control number assigned to the \n                prescription drug by the manufacturer of the \n                prescription drug.\n                    ``(I) The name, address, telephone number, and \n                professional license number (if any) of the importer.\n                    ``(J)(i) In the case of a prescription drug that is \n                shipped directly from the first foreign recipient of \n                the prescription drug from the manufacturer:\n                            ``(I) Documentation demonstrating that the \n                        prescription drug was received by the recipient \n                        from the manufacturer and subsequently shipped \n                        by the first foreign recipient to the importer.\n                            ``(II) Documentation of the quantity of \n                        each lot of the prescription drug received by \n                        the first foreign recipient demonstrating that \n                        the quantity being imported into the United \n                        States is not more than the quantity that was \n                        received by the first foreign recipient.\n                            ``(III)(aa) In the case of an initial \n                        imported shipment, documentation demonstrating \n                        that each batch of the prescription drug in the \n                        shipment was statistically sampled and tested \n                        for authenticity and degradation.\n                            ``(bb) In the case of any subsequent \n                        shipment, documentation demonstrating that a \n                        statistically valid sample of the shipment was \n                        tested for authenticity and degradation.\n                    ``(ii) In the case of a prescription drug that is \n                not shipped directly from the first foreign recipient \n                of the prescription drug from the manufacturer, \n                documentation demonstrating that each batch in each \n                shipment offered for importation into the United States \n                was statistically sampled and tested for authenticity \n                and degradation.\n                    ``(K) Certification from the importer or \n                manufacturer of the prescription drug that the \n                prescription drug--\n                            ``(i) is approved for marketing in the \n                        United States; and\n                            ``(ii) meets all labeling requirements \n                        under this Act.\n                    ``(L) Laboratory records, including complete data \n                derived from all tests necessary to ensure that the \n                prescription drug is in compliance with established \n                specifications and standards.\n                    ``(M) Documentation demonstrating that the testing \n                required by subparagraphs (J) and (L) was conducted at \n                a qualifying laboratory.\n                    ``(N) Any other information that the Secretary \n                determines is necessary to ensure the protection of the \n                public health.\n            ``(2) Maintenance by the secretary.--The Secretary shall \n        maintain information and documentation submitted under \n        paragraph (1) for such period of time as the Secretary \n        determines to be necessary.\n    ``(e) Testing.--The regulations under subsection (b) shall \nrequire--\n            ``(1) that testing described in subparagraphs (J) and (L) \n        of subsection (d)(1) be conducted by the importer or by the \n        manufacturer of the prescription drug at a qualified \n        laboratory;\n            ``(2) if the tests are conducted by the importer--\n                    ``(A) that information needed to--\n                            ``(i) authenticate the prescription drug \n                        being tested; and\n                            ``(ii) confirm that the labeling of the \n                        prescription drug complies with labeling \n                        requirements under this Act;\n                be supplied by the manufacturer of the prescription \n                drug to the pharmacist or wholesaler; and\n                    ``(B) that the information supplied under \n                subparagraph (A) be kept in strict confidence and used \n                only for purposes of testing or otherwise complying \n                with this Act; and\n            ``(3) may include such additional provisions as the \n        Secretary determines to be appropriate to provide for the \n        protection of trade secrets and commercial or financial \n        information that is privileged or confidential.\n    ``(f) Registration of Foreign Sellers.--Any establishment within \nCanada engaged in the distribution of a prescription drug that is \nimported or offered for importation into the United States shall \nregister with the Secretary the name and place of business of the \nestablishment.\n    ``(g) Suspension of Importation.--The Secretary shall require that \nimportations of a specific prescription drug or importations by a \nspecific importer under subsection (b) be immediately suspended on \ndiscovery of a pattern of importation of the prescription drugs or by \nthe importer that is counterfeit or in violation of any requirement \nunder this section, until an investigation is completed and the \nSecretary determines that the public is adequately protected from \ncounterfeit and violative prescription drugs being imported under \nsubsection (b).\n    ``(h) Approved Labeling.--The manufacturer of a prescription drug \nshall provide an importer written authorization for the importer to \nuse, at no cost, the approved labeling for the prescription drug.\n    ``(i) Prohibition of Discrimination.--\n            ``(1) In general.--It shall be unlawful for a manufacturer \n        of a prescription drug to discriminate against, or cause any \n        other person to discriminate against, a pharmacist or \n        wholesaler that purchases or offers to purchase a prescription \n        drug from the manufacturer or from any person that distributes \n        a prescription drug manufactured by the drug manufacturer.\n            ``(2) Discrimination.--For the purposes of paragraph (1), a \n        manufacturer of a prescription drug shall be considered to \n        discriminate against a pharmacist or wholesaler if the \n        manufacturer enters into a contract for sale of a prescription \n        drug, places a limit on supply, or employs any other measure, \n        that has the effect of--\n                    ``(A) providing pharmacists or wholesalers access \n                to prescription drugs on terms or conditions that are \n                less favorable than the terms or conditions provided to \n                a foreign purchaser (other than a charitable or \n                humanitarian organization) of the prescription drug; or\n                    ``(B) restricting the access of pharmacists or \n                wholesalers to a prescription drug that is permitted to \n                be imported into the United States under this section.\n    ``(j) Charitable Contributions.--Notwithstanding any other \nprovision of this section, section 801(d)(1) continues to apply to a \nprescription drug that is donated or otherwise supplied at no charge by \nthe manufacturer of the drug to a charitable or humanitarian \norganization (including the United Nations and affiliates) or to a \ngovernment of a foreign country.\n    ``(k) Waiver Authority for Importation by Individuals.--\n            ``(1) Declarations.--Congress declares that in the \n        enforcement against individuals of the prohibition of \n        importation of prescription drugs and devices, the Secretary \n        should--\n                    ``(A) focus enforcement on cases in which the \n                importation by an individual poses a significant threat \n                to public health; and\n                    ``(B) exercise discretion to permit individuals to \n                make such importations in circumstances in which--\n                            ``(i) the importation is clearly for \n                        personal use; and\n                            ``(ii) the prescription drug or device \n                        imported does not appear to present an \n                        unreasonable risk to the individual.\n            ``(2) Waiver authority.--\n                    ``(A) In general.--The Secretary may grant to \n                individuals, by regulation or on a case-by-case basis, \n                a waiver of the prohibition of importation of a \n                prescription drug or device or class of prescription \n                drugs or devices, under such conditions as the \n                Secretary determines to be appropriate.\n                    ``(B) Guidance on case-by-case waivers.--The \n                Secretary shall publish, and update as necessary, \n                guidance that accurately describes circumstances in \n                which the Secretary will consistently grant waivers on \n                a case-by-case basis under subparagraph (A), so that \n                individuals may know with the greatest practicable \n                degree of certainty whether a particular importation \n                for personal use will be permitted.\n            ``(3) Drugs imported from canada.--In particular, the \n        Secretary shall by regulation grant individuals a waiver to \n        permit individuals to import into the United States a \n        prescription drug that--\n                    ``(A) is imported from a licensed pharmacy for \n                personal use by an individual, not for resale, in \n                quantities that do not exceed a 90-day supply;\n                    ``(B) is accompanied by a copy of a valid \n                prescription;\n                    ``(C) is imported from Canada, from a seller \n                registered with the Secretary;\n                    ``(D) is a prescription drug approved by the \n                Secretary under chapter V;\n                    ``(E) is in the form of a final finished dosage \n                that was manufactured in an establishment registered \n                under section 510; and\n                    ``(F) is imported under such other conditions as \n                the Secretary determines to be necessary to ensure \n                public safety.\n    ``(l) Studies; Reports.--\n            ``(1) By the institute of medicine of the national academy \n        of sciences.--\n                    ``(A) Study.--\n                            ``(i) In general.--The Secretary shall \n                        request that the Institute of Medicine of the \n                        National Academy of Sciences conduct a study \n                        of--\n                                    ``(I) importations of prescription \n                                drugs made under the regulations under \n                                subsection (b); and\n                                    ``(II) information and \n                                documentation submitted under \n                                subsection (d).\n                            ``(ii) Requirements.--In conducting the \n                        study, the Institute of Medicine shall--\n                                    ``(I) evaluate the compliance of \n                                importers with the regulations under \n                                subsection (b);\n                                    ``(II) compare the number of \n                                shipments under the regulations under \n                                subsection (b) during the study period \n                                that are determined to be counterfeit, \n                                misbranded, or adulterated, and compare \n                                that number with the number of \n                                shipments made during the study period \n                                within the United States that are \n                                determined to be counterfeit, \n                                misbranded, or adulterated; and\n                                    ``(III) consult with the Secretary, \n                                the United States Trade Representative, \n                                and the Commissioner of Patents and \n                                Trademarks to evaluate the effect of \n                                importations under the regulations \n                                under subsection (b) on trade and \n                                patent rights under Federal law.\n                    ``(B) Report.--Not later than 2 years after the \n                effective date of the regulations under subsection (b), \n                the Institute of Medicine shall submit to Congress a \n                report describing the findings of the study under \n                subparagraph (A).\n            ``(2) By the comptroller general.--\n                    ``(A) Study.--The Comptroller General of the United \n                States shall conduct a study to determine the effect of \n                this section on the price of prescription drugs sold to \n                consumers at retail.\n                    ``(B) Report.--Not later than 18 months after the \n                effective date of the regulations under subsection (b), \n                the Comptroller General of the United States shall \n                submit to Congress a report describing the findings of \n                the study under subparagraph (A).\n    ``(m) Construction.--Nothing in this section limits the authority \nof the Secretary relating to the importation of prescription drugs, \nother than with respect to section 801(d)(1) as provided in this \nsection.\n    ``(n) Authorization of Appropriations.--There are authorized to be \nappropriated such sums as are necessary to carry out this section.''.\n    (b) Conforming Amendments.--The Federal Food, Drug, and Cosmetic \nAct is amended--\n            (1) in section 301(aa) (21 U.S.C. 331(aa)), by striking \n        ``covered product in violation of section 804'' and inserting \n        ``prescription drug in violation of section 804'';\n            (2) in section 303(a)(6) (21 U.S.C. 333(a)(6), by striking \n        ``covered product pursuant to section 804(a)'' and inserting \n        ``prescription drug under section 804(b)''."
}